Levi Sani of Nalagenetics represents a new generation of entrepreneurs seeking to apply innovations to Indonesia's beleaguered healthcare sector. A champion of the rapidly emerging "pharmacogenomics" field (the study of how genes affect a person's response to drugs), Nalagenetics has also leveraged its focus on Southeast Asian populations to roll out a number of critical diagnostic solutions in Indonesia's battle against COVID-19.
(Transkrip Bahasa Indonesia di sini)